3,337 Shares in argenx SE (NASDAQ:ARGX) Bought by XTX Topco Ltd

XTX Topco Ltd purchased a new position in argenx SE (NASDAQ:ARGX) in the second quarter, HoldingsChannel.com reports. The institutional investor purchased 3,337 shares of the company’s stock, valued at approximately $1,435,000.

Other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP lifted its position in argenx by 26.2% in the fourth quarter. Wellington Management Group LLP now owns 279,168 shares of the company’s stock worth $106,204,000 after buying an additional 57,956 shares during the last quarter. Sectoral Asset Management Inc. lifted its position in shares of argenx by 717.2% during the fourth quarter. Sectoral Asset Management Inc. now owns 10,027 shares of the company’s stock worth $3,815,000 after purchasing an additional 8,800 shares during the last quarter. Boxer Capital LLC lifted its position in shares of argenx by 88.2% during the fourth quarter. Boxer Capital LLC now owns 160,000 shares of the company’s stock worth $60,869,000 after purchasing an additional 75,000 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of argenx by 9.1% during the fourth quarter. The Manufacturers Life Insurance Company now owns 47,583 shares of the company’s stock worth $18,102,000 after purchasing an additional 3,967 shares during the last quarter. Finally, Altitude Crest Partners Inc. bought a new stake in shares of argenx during the fourth quarter worth $11,223,000. 60.32% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on ARGX. JPMorgan Chase & Co. lifted their target price on argenx from $500.00 to $640.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. William Blair reiterated a “market perform” rating on shares of argenx in a research report on Monday, June 17th. Guggenheim lifted their target price on argenx from $545.00 to $585.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Truist Financial lifted their target price on argenx from $480.00 to $540.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. Finally, Wells Fargo & Company lifted their price objective on argenx from $543.00 to $547.00 and gave the company an “overweight” rating in a report on Friday, July 26th. Three equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $547.74.

argenx Price Performance

ARGX opened at $533.00 on Friday. The business’s 50-day moving average is $512.59 and its two-hundred day moving average is $432.45. argenx SE has a 1 year low of $327.73 and a 1 year high of $554.74. The firm has a market capitalization of $31.68 billion, a PE ratio of -94.17 and a beta of 0.62.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, July 25th. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $1.34. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. The company had revenue of $489.43 million for the quarter, compared to analyst estimates of $436.66 million. During the same quarter in the previous year, the firm earned ($1.69) earnings per share. As a group, sell-side analysts expect that argenx SE will post -0.37 EPS for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.